Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience

Aleksandar Radujkovic, Sascha Dietrich, Tilmann Bochtler, Alwin Kraemer, Tilman Schöning, Anthony D. Ho, Peter Dreger, Thomas Luft

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

We retrospectively analyzed and compared the efficacy and toxicity of azacitidine (AZA) and low-dose cytarabine (LD-Ara-C) in 65 palliative patients with acute myeloid leukemia (AML) showing high bone marrow blast counts (≥30%) before start of treatment. Twenty-seven and 38 patients received AZA and LD-Ara-C, respectively. The median patient age was 71 yr. Patient and disease characteristics did not differ between the treatment groups, except for BM blast counts, and peripheral leukocyte and blast counts which were significantly higher in the LD-Ara-C group. AZA and LD-Ara-C were first-line treatment in 12 (44%) and 17 patients (45%), respectively. Response and hematologic improvement rates were low and similar in both treatment groups. In both treatment groups, most common non-hematologic toxicities included febrile neutropenia, pneumonia, and bleedings without significant differences regarding frequencies. Estimated 1-yr survival rates were 15% (95% CI 8-22) and 13% (95% CI 7-19) in the AZA and LD-Ara-C groups, respectively, without statistically significant difference. In multivariate analysis (n = 65), previous treatment (HR 2.27, 95% CI 1.00-5.22, P = 0.05) and adverse cytogenetics (HR 2.50, 95% CI 1.20-5.22, P = 0.02) were independent predictors of poor survival. In our center and within the limitations of a retrospective study, both treatment regimens showed similar but limited efficacy in palliative patients with AML and high BM blast counts.

Original languageEnglish (US)
Pages (from-to)112-117
Number of pages6
JournalEuropean Journal of Haematology
Volume93
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Azacitidine
Cytarabine
Acute Myeloid Leukemia
Bone Marrow
Therapeutics
Febrile Neutropenia
Leukocyte Count
Cytogenetics
Pneumonia
Multivariate Analysis
Survival Rate
Retrospective Studies
Hemorrhage
Survival

Keywords

  • Acute myeloid leukemia
  • Azacitidine
  • Cytarabine
  • Retrospective

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience. / Radujkovic, Aleksandar; Dietrich, Sascha; Bochtler, Tilmann; Kraemer, Alwin; Schöning, Tilman; Ho, Anthony D.; Dreger, Peter; Luft, Thomas.

In: European Journal of Haematology, Vol. 93, No. 2, 2014, p. 112-117.

Research output: Contribution to journalArticle

Radujkovic, Aleksandar ; Dietrich, Sascha ; Bochtler, Tilmann ; Kraemer, Alwin ; Schöning, Tilman ; Ho, Anthony D. ; Dreger, Peter ; Luft, Thomas. / Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience. In: European Journal of Haematology. 2014 ; Vol. 93, No. 2. pp. 112-117.
@article{b163b34658654139bfdadba58e40520c,
title = "Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience",
abstract = "We retrospectively analyzed and compared the efficacy and toxicity of azacitidine (AZA) and low-dose cytarabine (LD-Ara-C) in 65 palliative patients with acute myeloid leukemia (AML) showing high bone marrow blast counts (≥30{\%}) before start of treatment. Twenty-seven and 38 patients received AZA and LD-Ara-C, respectively. The median patient age was 71 yr. Patient and disease characteristics did not differ between the treatment groups, except for BM blast counts, and peripheral leukocyte and blast counts which were significantly higher in the LD-Ara-C group. AZA and LD-Ara-C were first-line treatment in 12 (44{\%}) and 17 patients (45{\%}), respectively. Response and hematologic improvement rates were low and similar in both treatment groups. In both treatment groups, most common non-hematologic toxicities included febrile neutropenia, pneumonia, and bleedings without significant differences regarding frequencies. Estimated 1-yr survival rates were 15{\%} (95{\%} CI 8-22) and 13{\%} (95{\%} CI 7-19) in the AZA and LD-Ara-C groups, respectively, without statistically significant difference. In multivariate analysis (n = 65), previous treatment (HR 2.27, 95{\%} CI 1.00-5.22, P = 0.05) and adverse cytogenetics (HR 2.50, 95{\%} CI 1.20-5.22, P = 0.02) were independent predictors of poor survival. In our center and within the limitations of a retrospective study, both treatment regimens showed similar but limited efficacy in palliative patients with AML and high BM blast counts.",
keywords = "Acute myeloid leukemia, Azacitidine, Cytarabine, Retrospective",
author = "Aleksandar Radujkovic and Sascha Dietrich and Tilmann Bochtler and Alwin Kraemer and Tilman Sch{\"o}ning and Ho, {Anthony D.} and Peter Dreger and Thomas Luft",
year = "2014",
doi = "10.1111/ejh.12308",
language = "English (US)",
volume = "93",
pages = "112--117",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Azacitidine and low-dose cytarabine in palliative patients with acute myeloid leukemia and high bone marrow blast counts - a retrospective single-center experience

AU - Radujkovic, Aleksandar

AU - Dietrich, Sascha

AU - Bochtler, Tilmann

AU - Kraemer, Alwin

AU - Schöning, Tilman

AU - Ho, Anthony D.

AU - Dreger, Peter

AU - Luft, Thomas

PY - 2014

Y1 - 2014

N2 - We retrospectively analyzed and compared the efficacy and toxicity of azacitidine (AZA) and low-dose cytarabine (LD-Ara-C) in 65 palliative patients with acute myeloid leukemia (AML) showing high bone marrow blast counts (≥30%) before start of treatment. Twenty-seven and 38 patients received AZA and LD-Ara-C, respectively. The median patient age was 71 yr. Patient and disease characteristics did not differ between the treatment groups, except for BM blast counts, and peripheral leukocyte and blast counts which were significantly higher in the LD-Ara-C group. AZA and LD-Ara-C were first-line treatment in 12 (44%) and 17 patients (45%), respectively. Response and hematologic improvement rates were low and similar in both treatment groups. In both treatment groups, most common non-hematologic toxicities included febrile neutropenia, pneumonia, and bleedings without significant differences regarding frequencies. Estimated 1-yr survival rates were 15% (95% CI 8-22) and 13% (95% CI 7-19) in the AZA and LD-Ara-C groups, respectively, without statistically significant difference. In multivariate analysis (n = 65), previous treatment (HR 2.27, 95% CI 1.00-5.22, P = 0.05) and adverse cytogenetics (HR 2.50, 95% CI 1.20-5.22, P = 0.02) were independent predictors of poor survival. In our center and within the limitations of a retrospective study, both treatment regimens showed similar but limited efficacy in palliative patients with AML and high BM blast counts.

AB - We retrospectively analyzed and compared the efficacy and toxicity of azacitidine (AZA) and low-dose cytarabine (LD-Ara-C) in 65 palliative patients with acute myeloid leukemia (AML) showing high bone marrow blast counts (≥30%) before start of treatment. Twenty-seven and 38 patients received AZA and LD-Ara-C, respectively. The median patient age was 71 yr. Patient and disease characteristics did not differ between the treatment groups, except for BM blast counts, and peripheral leukocyte and blast counts which were significantly higher in the LD-Ara-C group. AZA and LD-Ara-C were first-line treatment in 12 (44%) and 17 patients (45%), respectively. Response and hematologic improvement rates were low and similar in both treatment groups. In both treatment groups, most common non-hematologic toxicities included febrile neutropenia, pneumonia, and bleedings without significant differences regarding frequencies. Estimated 1-yr survival rates were 15% (95% CI 8-22) and 13% (95% CI 7-19) in the AZA and LD-Ara-C groups, respectively, without statistically significant difference. In multivariate analysis (n = 65), previous treatment (HR 2.27, 95% CI 1.00-5.22, P = 0.05) and adverse cytogenetics (HR 2.50, 95% CI 1.20-5.22, P = 0.02) were independent predictors of poor survival. In our center and within the limitations of a retrospective study, both treatment regimens showed similar but limited efficacy in palliative patients with AML and high BM blast counts.

KW - Acute myeloid leukemia

KW - Azacitidine

KW - Cytarabine

KW - Retrospective

UR - http://www.scopus.com/inward/record.url?scp=84904307346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904307346&partnerID=8YFLogxK

U2 - 10.1111/ejh.12308

DO - 10.1111/ejh.12308

M3 - Article

C2 - 24628527

AN - SCOPUS:84904307346

VL - 93

SP - 112

EP - 117

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -